Century Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Cowan Chad acquired Company’s shares for reported $49252.0 on Dec 22 ’25. In the deal valued at $0.85 per share,58,060 shares were bought. As a result of this transaction, Cowan Chad now holds 1,045,087 shares worth roughly $2.13 million.
Then, Pfeiffenberger Brent bought 52,000 shares, generating $30,352 in total proceeds. Upon buying the shares at $0.58, the President and CEO now owns 3,322,990 shares.
Before that, Carr Douglas sold 257 shares. Century Therapeutics Inc shares valued at $137 were divested by the SVP Finance & Operations at a price of $0.53 per share. As a result of the transaction, Carr Douglas now holds 404,874 shares, worth roughly $0.83 million.
Rodman & Renshaw initiated its Century Therapeutics Inc [IPSC] rating to a Buy in a research note published on August 08, 2024; the price target was $6. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in late August from “an Overweight” to “a Neutral”. Chardan Capital Markets began covering IPSC with “Buy” recommendation on December 27, 2022. Guggenheim started covering the stock on October 31, 2022. It rated IPSC as “a Buy”.
Price Performance Review of IPSC
On Monday, Century Therapeutics Inc [NASDAQ:IPSC] saw its stock jump 5.15% to $2.04. Over the last five days, the stock has gained 105.15%. Century Therapeutics Inc shares have risen nearly 90.65% since the year began. Nevertheless, the stocks have risen 105.07% over the past one year.
How much short interest is there in Century Therapeutics Inc?
A steep rise in short interest was recorded in Century Therapeutics Inc stocks on 2025-12-31, dropping by -0.28 million shares to a total of 0.33 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 0.61 million shares. There was a decline of -86.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 10, 2022 when Canaccord Genuity began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
